Author

T. F. Rogers

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Organism:human· 6 Research Focus:drug response / drug discovery· 5 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

N. Beutler· 7 shared A. K. Chatterjee· 3 shared A. K. Gupta· 3 shared D. Huang· 3 shared D. R. Burton· 3 shared H. Liu· 3 shared I. A. Wilson· 3 shared M. A. Bakowski· 3 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

N. Beutler

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Covalent Warhead

N. G. R. D. Elshan, K. C. Wolff, L. Riva, A. K. Woods, G. Grabovyi, K. Wilson, A. Rahimi, J. Pedroarena, S. Ghorai, A. K. Gupta, A. Nazarian, F. Weiss, Y. Liu, W. Mazumdar, L. Song, , A. K. Chatterjee

This paper introduces CMX990, a potent SARS-CoV-2 3CL protease inhibitor with improved potency and clearance compared to nirmatrelvir, advancing to Phase 1 clinical trials.

bioRxiv · Oct 24, 2023Microbiology

Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple epitopes

J. Hurtado, T. F. Rogers, D. B. Jaffe, B. Adams, S. Bangaru, E. Garcia, T. Capozzola, T. Messmer, P. Sharma, G. Song, N. Beutler, W. He, K. Dueker, R. Musharrafieh, M. J. T. Stubbington, , B. Briney

The paper identifies two broadly neutralizing antibodies against coronaviruses by screening B cell repertoires, showing they target different epitopes and offer protection against variants.

bioRxiv · Mar 28, 2023Immunology

Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infection

C.-k. Oh, T. Nakamura, N. Beutler, X. Zhang, J. Pina-Crespo, M. Talantova, S. Ghatak, D. Trudler, L. N. Carnevale, S. R. McKercher, M. A. Bakowski, J. K. Diedrich, A. J. Roberts, A. K. Woods, V. Chi, , S. A. Lipton

This paper develops aminoadamantane nitrate compounds that inhibit SARS-CoV-2 infection by S-nitrosylating ACE2 and blocking viral entry, showing efficacy in vitro and in a Syrian hamster model.

bioRxiv · Apr 5, 2022Microbiology

Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19

M. A. Bakowski, N. Beutler, E. Chen, T.-T. H. Nguyen, M. G. Kirkpatrick, M. Parren, L. Yang, J. Ricketts, A. K. Gupta, M. V. Hull, P. G. Schultz, D. R. Burton, A. K. Chatterjee, C. W. McNamara, T. F. Rogers

The paper identifies 66 compounds that inhibit SARS-CoV-2 replication and 24 that synergize with remdesivir, suggesting potential oral drug repositioning candidates for COVID-19.

Nature Communications · Jun 3, 2021Peer-reviewedMicrobiology

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants

H. Cho, K. K. Gonzales-Wartz, D. Huang, M. Yuan, M. Peterson, J. Liang, N. Beutler, J. L. Torres, Y. Cong, E. Postnikova, S. Bangaru, C. A. Talana, W. Shi, E. S. Yang, Y. Zhang, , J. Tan

This study identifies ultrapotent bispecific antibodies that neutralize emerging SARS-CoV-2 variants by targeting multiple spike protein regions, showing efficacy in vitro and in a hamster model.

bioRxiv · Apr 1, 2021 · PreprintImmunology

Adult Stem Cell-derived Complete Lung Organoid Models Emulate Lung Disease in COVID-19

C. Tindle, M. Fuller, A. Fonseca, S. Taheri, S.-R. Ibeawuchi, N. Beutler, G. Katkar, A. Claire, V. Castillo, M. Hernandez, H. Russo, J. Duran, L. E. Crotty Alexander, A. Tipps, G. Lin, , S. Das

This study develops a human lung organoid model to emulate COVID-19 pathogenesis, showing proximal airway cells drive viral infection while distal cells drive excessive immune response.

bioRxiv · Oct 17, 2020Cell Biology

Structural basis of a public antibody response to SARS-CoV-2

M. Yuan, H. Liu, N. C. Wu, C.-C. D. Lee, X. Zhu, F. Zhao, D. Huang, W. Yu, Y. Hua, H. Tien, T. F. Rogers, E. Landais, D. Sok, J. G. Jardine, D. R. Burton, I. A. Wilson

The paper identifies IGHV3-53 as a common VH gene for SARS-CoV-2 neutralizing antibodies and determines its structural basis for binding the RBD.

Science · Aug 28, 2020Peer-reviewedMicrobiology

Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model

T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W.-t. He, O. Limbo, C. Smith, G. Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, , D. Burton

This study rapidly identifies potent SARS-CoV-2 neutralizing antibodies and demonstrates their protective efficacy in an animal model.

bioRxiv · May 11, 2020Immunology